[go: up one dir, main page]

EP0107509B1 - Protein-A Material und dessen Herstellung - Google Patents

Protein-A Material und dessen Herstellung Download PDF

Info

Publication number
EP0107509B1
EP0107509B1 EP83306500A EP83306500A EP0107509B1 EP 0107509 B1 EP0107509 B1 EP 0107509B1 EP 83306500 A EP83306500 A EP 83306500A EP 83306500 A EP83306500 A EP 83306500A EP 0107509 B1 EP0107509 B1 EP 0107509B1
Authority
EP
European Patent Office
Prior art keywords
protein
amino acid
dna
nucleotide sequence
coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP83306500A
Other languages
English (en)
French (fr)
Other versions
EP0107509A3 (en
EP0107509A2 (de
Inventor
Donald A. Colbert
Algis Anilionis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Original Assignee
Repligen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corp filed Critical Repligen Corp
Priority to AT83306500T priority Critical patent/ATE71657T1/de
Publication of EP0107509A2 publication Critical patent/EP0107509A2/de
Publication of EP0107509A3 publication Critical patent/EP0107509A3/en
Application granted granted Critical
Publication of EP0107509B1 publication Critical patent/EP0107509B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Protein A is a constituent of the cell wall of the bacterium Staphylococcus aureus.
  • One form has a reported molecular weight of 42,000 and is a major component (1.7% of the total cell protein) of the cell wall.
  • Measurements of frictional ratio and intrinsic viscosity of protein A in comparison to most globular proteins suggest that its shape is relatively elongated.
  • Controlled trypsinization of the molecule reveals 4 homologous peptide domains (designated in order from the N-terminus as D, A, B, C), each of which can bind one molecule of IgG at the Fc region.
  • Sensitized peripheral blood lymphocytes normally responsible for cytotoxicity of tumor cells, are hypothesized to be inhibited in this function by serum blocking factors which are presumed to consist of specific antigens, antibodies, antiglobulins, and immune complexes. See Barnes, B.C. (1981) Cancer Bull. 33:278. These "blocking" factors can be removed from sera of tumor-bearers by absorption to Staphlococ- cus aureus, Cowan I cells which contain protein A, and thus allow cell-mediated tumor cell toxicity to proceed in in vitro test systems. See Steele, G., Ankerst, J., and Sjogren, H. (1974) Int. J. Cancer 14:83. Protein A also activates polyclonal antibody synthesis independent of its IgG binding activity. See Sjodahl, J. and Moller, G (1979) Scand. J. Immunol. 10:593.
  • plasmids comprising a novel nucleotide sequence coding for the amino acid sequence of protein A material and the known plasmid vector pBR322.
  • the sequence of this novel oligonucleotide follows as SEQUENCE I.
  • the entire sequence is contained in plasmid pAC37 (NRRL B-15127).
  • Plasmid pAC37-6 (NRRL B-15131) contains the same entire sequence except for the last 209 nucleotide bases.
  • the last six nucleotide bases of pAC37-6 code for the Pstl recognition sequence, i.e., CTGCAG.
  • nucleotide sequence and subfragments thereof enable persons in the art, for the first time, to obtain cloned nucleotide sequences coding for protein A material and subfragments of protein A material.
  • Protein A material of the subject invention can be used in the same manner as Protein A, disclosed above.
  • the invention provides not only a recombinant DNA molecule comprising (a) a nucleotide sequence coding for the amino acid sequence of a Protein A material, characterised in that said nucleotide sequence and said amino acid sequence are as in Sequence I or (b) a nucleotide sequence coding for the amino acid sequence of other Protein A materials having an additional IgG-binding domain equivalent to domain E of Sequence I; but also a recombinant DNA molecule comprising: (a) a nucleotide sequence coding for the amino acid sequence of domain E of a Protein A material, characterised in that said nucleotide sequence and said amino acid sequence are as follows: or; (b) a nucleotide sequence coding for the amino acid sequence of other Protein A materials having an additional IgG-binding domain equivalent to said domain E.
  • the invention also provides a micro-organism comprising a recombinant plasmid containing a nucleotide sequence defined according to the invention, or fragments thereof, said fragments containing domain E or said additional IgG-binding domain equivalent to domain E.
  • the nucleotide sequence may be absent the last 209 nucleotide bases of Sequence I.
  • the invention also provides a DNA transfer vector comprising a nucleotide sequence encoding an amino acid sequence, said amino acid sequence being defined according to the invention; and a micro-organism transferred by such a DNA transfer vector.
  • the invention also provides a micro-organism comprising a recombinant plasmid containing a mixture of nucleotide sequences of domains D, A, B and C as defined in Sequence I coding for amino acid sequences of Protein A material characterised in that said mixture of nucleotide sequences also exhibits a domain E as defined in Sequence I or other additional IgG-binding domain equivalent to domain E.
  • the invention also provides an essentially pure biological material having a nucleotide sequence coding for the amino acid sequence of a Protein A material, said nucleotide sequence being defined according to the invention.
  • the invention also provides a process for preparing a Protein A material, which comprises expression of cloned DNA as defined according to the invention, coding for said Protein A material, in a suitable microbial host, and recovering said Protein A material.
  • Cloning of the DNA sequences coding for protein A material was initiated by construction of a gene bank comprising DNA sequences of the SAC genome (S. aureus, Cowan I, SAC, ATCC 12598). This was accomplished by G-C tailing using blunt-end SAC DNA fragments generated by Haelll+Alul partial restriction digestion as substrate. Digestion of 250 /1.g SAC DNA in 400 ⁇ l 50 mM Tris-HCI, pH 7.5; 5 mM MgCI; 1 mM dithiothreitol (DTT) with 150 units Haelll and 200 units Alul (12 min., 37 C) generated a broad size range of DNA fragments (2-10 kilobase pairs [kb]).
  • the coding sequences of protein A should comprise 1.1-1.2 kb of DNA.
  • larger fragments, 3-6 kb were used for construction of the SAC gene bank. This DNA was extracted from a preparative agarose gel, tailed with 15-20 C residues with terminal transferase, and annealed to G-tailed, Pstl-digested pBR322. Transformation of E.
  • coli MS371 cells with the resulting recombinant DNA, G-tailed plasmid DNA alone, or uncut pBR322 yielded transformation efficiencies of 2.0 x 10 4 , 5.0 x 10 2 , and 2.0 x 10 6 transformants per ⁇ g plasmid DNA, respectively. Approximately 7.0 x 10 3 transformants were picked onto fresh tetracycline plates for screening.
  • Mini-lysate plasmid DNA preparations for 10 randomly picked transformants were digested with Pstl and the sizes of the resulting DNA fragments analyzed by agarose gel electrophoresis. The results indicated that (1) 9 of 10 transformants carried recombinant DNA plasmids, (2) 7 of 9 recombinant plasmids had both Pstl restriction sites regenerated by the G-C tailing procedure, and (3) the average insert length was approximately 3.0 kb.
  • the cloning vehicles embodying the invention are useful to make available for the first time and to increase the supply of the gene coding for molecules with protein A-like biological activity by replication of a transformed host. With this abundance of the desired gene, levels of protein A expression necessary to make protein A-like material available at a lower cost can be predicted.
  • Staphylococcus aureus, Cowan I (SAC, ATCC 12598) and Woods 46 (SAW, ATCC 10832) strains were obtained from the American Type Culture Collection, Rockville, Maryland, Both strains were grown (liquid or 1.5% agar plates) in Penassay medium (5 mg/ml Casitone, 2.5 mg/ml yeast extract, 2.5 mg/ml 3- glycerophosphate, 4 mg/ml niacin, 2 mg/ml thiamine-HCI) under standard conditions.
  • Penassay medium 5 mg/ml Casitone, 2.5 mg/ml yeast extract, 2.5 mg/ml 3- glycerophosphate, 4 mg/ml niacin, 2 mg/ml thiamine-HCI
  • E. coli MS371 was propagated in L-broth (5 g/I NaCI, 10 g/I bactotryptone, 5 g/1 yeast extract).
  • L-broth 5 g/I NaCI, 10 g/I bactotryptone, 5 g/1 yeast extract.
  • plasmid DNA preparation cells containing plasmids of interest were grown in M-9 media (49 mM Na 2 HP0 4 , 17 mM KH 2 P0 4 , 8.6 mM NaCI, 18.7 mM NH 4 CI, 0.1 mM CaCl 2 , 1 mM MgSO 4 ⁇ 7 H20, 0.4% glucose, 0.4% casamino acids, 2 mg/ml thiamine).
  • the frozen cell suspension was allowed to thaw at 37° C, 50 mg/ml lysostaphin (Sigma Chemical Co., St. Louis, Mo.) was added, and the suspension incubated at 37° C, 15 min. Protease K (40 mg/ml) and SDS (0.5%) were added and the mixture incubated at 37 C, 1 hour.
  • the lysate was then extracted with phenol:chloroform (1:1) saturated with DNA extraction buffer.
  • the SAC DNA solution was adjusted to 0.95 g/ml CsCI and banded by centrifugation (44K rpm, 46 hours, 23 C with a Beckman Ti60 rotor). The DNA was then harvested with a syringe and 21 g needle by side puncture.
  • the DNA was dialyzed against TE buffer (10 mM Tris-HCI: 1 mM EDTA, pH 8.0), phenol:chloroform-extracted as before, and precipitated twice with 2 volumes ethanol. Yields of SAC DNA ranged between 700-800 mg DNA per gram wet weight of cells.
  • restriction endonucleases were purchased from Bethesda Research Laboratories, Bethesda, Md. or New England Biolabs, Beverly, Mass. Unless otherwise indicated, restriction digests, described herein, were carried out at DNA concentrations of 100-400 ⁇ g/ml, 2-4 units enzyme per ⁇ g DNA, 2-3 hours, 37° C, in buffer systems recommended for each enzyme by the respective company.
  • Agarose gel electrophoresis was carried out using a 2X Tris-acetate gel buffer (80 mM Tris-HCI, pH 8.0; 40 mM NaC 2 H 3 0 2 ; 36 mM NaCI; 2 mM Na 2 EDTA) in the gel and 1X buffer for the run.
  • Analytical gels were routinely run as "submarine gels" in a horizontal gel box.
  • Preparative gels were routinely run in an EC Model 470 gel box. DNA bands were visualized by ethidium bromide (EtBr) post-staining (0.5 mg/ml in 1X gel buffer) and use of a U.V. transilluminator Model TM-36 from Ultra-Violet Products, Inc., San Gabriel, Ca.
  • Extraction of DNA from preparative agarose gels was initiated by visualization of the positions of EtBr- stained bands of a single gel lane.
  • Gel slices containing DNA fragments of interest were diced manually and passed through a 20 g needle with 12-2 volumes DNA gel extraction buffer (0.5 M NH 4 C 2 H 3 0 2 , 10 mM EDTA, 10 mM Mg(C 2 H 3 0 2 ) 2 , 0.1% SDS).
  • An equal volume of phenol saturated with 1 mM NH 4 C 2 H 3 0 2 , 10 mM EDTA was added and extraction carried out in eppendorf tubes on a rotary shaker at 23°C overnight. The tubes were then placed on ice for 30 min.
  • Target SAC DNA fragments of average 3-5 kb length were tailed with 15-20 C residues in a 30 ⁇ l reaction under the following conditions: 4-5 ⁇ g SAC DNA, 20 ⁇ M dCTP, 200 mM K/cacodylate, 1 mM CoCl 2 , 1 mM ⁇ -SH, 4.5 units terminal deoxynucleotidyl transferase; 37° C, 12 min. Termination of the reaction and treatment of C-tailed SAC DNA was carried out as described above.
  • Annealing of plasmid and target SAC DNA was initiated by mixing 2.5 ⁇ g plasmid and 4.0 ⁇ g target SAC DNA in 300 ⁇ l 10 mM Tris-HCI, pH 8.0; 1 mM EDTA; 100 mM NaCI; and heating for 10 min. at 68° C. The annealing solution was then allowed to incubate 1 hour at 55° C, 1 hour at 23° C, and was stored at 4° C until needed.
  • T 4 DNA ligase (Bethesda Research Laboratories); 66 ⁇ M ATP; 66 mM Tris-HCI, pH 7.6; 6.6 mM MgCl 2 ; 10 mM dithiothreitol; at 12° C, 12-16 hours.
  • the cells were pelleted (5 min. 5K rpm, 5°C in a JA20 rotor in a Beckman J2-20 centrifuge), resuspended in half the original volume of ice-cold 50 mM MnCl 2 ; 10 mM NaC 2 H 3 0 2 , pH 5.6; and allowed to stand at 0°C, 20 min. Following pelleting of the cells as above, they were resuspended in ice-cold 100 mM MnCl 2 ; 75 mM CaCl 2 ; 10 mM NaC 2 H 3 0 2 , pH 5.6.
  • a 0.1 ml aliquot of cells was mixed with 10 ⁇ l DNA transformation solution and allowed to sit on ice 40 min. The cells were then subjected to heat shock (2.5 min., 25-30 C) and 1.5 ⁇ l 2.0 M Tris-HCI, pH 7.4, and 0.5 ml L-broth per 0.1 ml cell aliquot were added. The cells were then plated in 15-25 ⁇ l aliquots on 1.5% agar L-broth plates supplemented with 10 ⁇ g/ml tetracycline (Sigma) and incubated overnight at 37°C. Transformation efficiencies of 1.0 x 10 7 colonies per ⁇ g pBR322 DNA were routinely observed.
  • Mini-lysate plasmid preparation was initiated by addition of 1 ml of fresh overnight culture to 9 ml L-broth, supplemented with 1% glucose and allowed to grow with shaking at 37°C to an OD 550 of 1.0. Chloramphenicol was then added to 150 ⁇ g/ml and the culture incubated for 12-16 hours at 37 C. The cells were then pelleted by centrifugation (5 min., 3K rpm, 23° C in an RC-3 centrifuge), resuspended in ice-cold TE buffer, and transferred to a 1.5 ml eppendorf tube to be repelleted by centrifugation.
  • the resulting cell pellet was resuspended in 50 mM Tris-HCI, pH 8.0; 50 mM EDTA; 15% sucrose (wt/vol) by vortexing.
  • 10 ⁇ l of 10% SDS were added and incubated at 70°C, 10 min.
  • 62.5 ⁇ l ice-cold 4 M potassium acetate was added and the lysate allowed to stand for at least 2 hours on ice.
  • the supernatant volume was adjusted to 0.5 ml with H 2 0 and the DNA precipitated with 2 volumes absolute ethanol.
  • the DNA was then resuspended in 100 ⁇ l TE, the salt adjusted to 0.1 M with NaCI, and re-precipitated with two volumes ethanol prior to restriction enzyme analysis.
  • Preparation of cleared lysates was initiated by suspending the cell pellet in 6.25 ml per liter original culture of 25% sucrose in 50 mM Tris-HCI, pH 8.0, and then adding 1.5 ml of a freshly made 10 mg/ml lysozyme (Sigma) solution. After continuous swirling of the suspension on ice for 5 min., 1.25 ml of 0.5 M Na 2 EDTA, pH 8.0, was added and swirling of the suspension on ice continued for 5 min.
  • the plasmid DNA band on the gradient is visualized with a U.V. lamp and harvested with a syringe by side puncture using a 21 g needle. Removal of EtBr is carried out by repeated isobutyl alcohol extraction. The plasmid solution is then dialyzed overnight against TE buffer, the salt concentration adjusted to 0.1 M NaCl and precipitation of DNA carried out with 2 volumes of absolute ethanol.
  • Lysis of filter-bound cells was accomplished by laying the filters (colony side up) on sheets of Whatman 3MM filter paper saturated with 0.5 M NaOH and allowing lysis to proceed for 10 min. at 23 C. Following lysis, the filters were blot dried and neutralized on filter paper saturated with 1.0 M Tris-HCI, pH 7.0. The filters were again blot dried and pre-treated with protein binding solution (10 mM Tris-HCI, pH 7.0; 100 mM NaCI; 5 mM EDTA; 0.13% NP40; 0.1% SDS; 0.1% sodium deoxycholate; 0.2% Ficoll 400: 0.3% gelatin) for 4-6 hours at 23 C on a rotary platform shaker.
  • protein binding solution (10 mM Tris-HCI, pH 7.0; 100 mM NaCI; 5 mM EDTA; 0.13% NP40; 0.1% SDS; 0.1% sodium deoxycholate; 0.2% Ficoll 400: 0.3% gelatin
  • the filters were transferred to a 1-liter beaker containing a 4.5 ml/filter protein-binding solution. Binding of 125 I-IgG (Goat anti-rabbit, New England Nuclear, Boston, MA) was carried out by the addition of 5 x 10 6 cpm/ml 125 I-IgG to the beaker and allowing binding to occur at 4°C overnight with constant rotary shaking. Washing of the filters was accomplished by repeated washing with 500 ml protein-binding solutions: the first wash carried out at 4°C, and 2-3 additional washes carried out at 23 C. The washed filters were then dried by blotting and detection of 125 I-IgG binding accomplished by radioautography, using Kodak XAR-5 film and two DuPont Cronex Lightning-Plus enhancement screens.
  • 125 I-IgG Goat anti-rabbit, New England Nuclear, Boston, MA
  • pAc37 plasmid DNA Restriction endonuclease analysis of pAc37 plasmid DNA indicated the presence of Pstl insert fragments of 3.1, 2.3, 1.9, and 0.65 kb length.
  • pAc37 plasmid DNA was digested with Pstl, re-ligated with T4 ligase, and used to transform E. coli MS371 cells. The resulting transformants were screened by the 121 I-IgG-binding assay as described in Example 12.
  • the position of the sequences coding for the B-C junction of the protein A-like material within the insert made it likely that the 1.9 kb insert of pAc37-6 plasmid DNA contained most of the sequences coding for the protein A gene, including the ribosome binding site, and 5' regulatory sequences.
  • E. coli MS371 (pAc37-6) is lysed with 0.1 N NaOH and centrifuged. The supernatant is removed and 25 mM monobasic sodium phosphate is added and the solution adjusted to pH 7.0 with 1 M HCI. The protein solution is dialyzed against 25 mM sodium phosphate pH 7.0, then clarified by centrifugation.
  • the solution is applied to an IgG-Sepharose column (30 ml bed volume per 1.3 gm of protein) and the column washed with 0.1 M sodium phosphate pH 7.0 until no protein, as determined by A 28 o, elutes from the column.
  • Protein A material is eluted with 0.1 M glycine" HCI.
  • the purified protein is concentrated by precipitation with 80% saturated (NH 4 ) 2 S0 4 , dialyzed versus 10 mM sodium phosphate pH 7.0, and stored frozen.
  • Restriction enzymes can be used to cleave the nucleotide sequence coding for protein A material in order to isolate essentially pure subfragments of the coding region that are capable of coding for amino acid sequences with biological activities similar to those of protein A. For example, cleavage of pAc37-6 DNA with Rsal restriction endonuclease will yield an oligonucleotide that is 1,199 nucleotides long and that codes for a polypeptide containing domains E, D, A, B, and C.
  • Digestion with other restriction enzymes such as Hinfl, or a combination of enzymes such as Hindlll and Sau3A, can be used to generate essentially pure, well-defined oligonuclectide subfragments that code for amino acid sequences with biological activities similar to those of protein A.
  • the desired oligonucleotide subfragments are isolated in their essentially pure form by preparative agarose gel electrophoresis as follows: Agarose is dissolved to 1% in 2x E buffer (0.08 M Tris ⁇ HCl, pH 7.8; 0.01 M NaC 2 H 3 0 2 ; 0.002 M EDTA) and poured into a Bio-Rad (Richmond, Ca) slab gel apparatus. Samples are dissolved in 10 mM Tris ⁇ Cl, pH 8.0; 0.1 mM EDTA and the samples are run at constant power with 2x E running buffer.
  • one lane is cut from the gel, stained with ethidium bromide (0.5 ⁇ gm/ml) and the DNA bands visualized under ultraviolet light.
  • the band of interest is cut from the rest of the gel and macerated before passing it through a 20 gauge needle.
  • An equal weight of extraction buffer (10 mM Tris ⁇ HCl, pH 8.0; 2 mM EDTA; 1 M NaCI) is then added and mixed with the gel. The mixture is incubated at 47° C for 16 hours and the agarose pelleted at 100,000 x g for 1 hour. The supernatant is then made 30 agm/ml in tRNA and extracted with phenol until no agarose is visible at the interface. The DNA is then ether extracted and ethanol precipitated. Gel buffers and extraction procedures can be varied by one skilled in the art to recover the desired DNA fragments.
  • the oligonucleotide coding for the amino acid sequence can be synthesized chemically.
  • the coding region, or the entire coding region for a Protein A-like molecule can be synthesized and isolated in their essentially pure forms; this includes those regions of the coding sequence coding for domains E, D, A, B and C.
  • Domain E alone, or in various combinations with any of Domains D, A, B and C, is useful in the same manner as Protein A to bind IgG in diagnostic test systems, as described previously.
  • the essentially pure nucleotide sequences coding for Protein A material or for biologically active subfragments of Protein A material, isolated and synthesized as described in Examples 16 and 17, respectively, can be ligated into appropriate restriction enzyme sites in an expression cloning vector. If necessary, sites can be added to nucleotide sequences using linker molecules. (See, for example, Norris, K.E., et al. [1979] Gene 7: 355-362). The ligated DNA can then be used to transform a host organism. Previous work by others has shown that expression of the cloned nucleotide sequence would be expected. (See, for example, Doel, M.T. et al. [1980] Nuc. Acids Res.
  • Plasmids pAc37 and pAc37-6 have been deposited in an E. coli host in the permanent collection of the Northern Regional Research Laboratory (NRRL), U.S. Department of Agriculture, Peoria, Illinois, U.S.A. Their accession numbers in this repository are as follows:
  • Plasmid pBR322 is a known and available plasmid. It is maintained in the E. coli host ATCC 37017. Purified pBR322 DNA can be obtained as described in Bolivar, F., Rodriquez, R.L., Greene, P.J., Betlach, M.C., Heyneker, H.L., Boyer, H.W., Crosa, J.H., and Falkow, S. (1977) Gene 2:95-113; and Sutcliffe, J.G. (1978) Nucleic Acids Res. 5:2721-2728.
  • NRRL B-15127, NRRL B-15131, and NRRL B-15129 are deposited in accordance with European Rule 28.
  • E. coli MS371 hosts which can be used instead of E. coli MS371, for example, B. subtilis, Streptomyces species, and yeast.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (12)

1. Rekombinantes DNA-Molekül, mit
a) einer Nucleotidsequenz zum Codieren einer Aminosäuresequenz der Domäne E eines Protein-A-Materials, dadurch gekennzeichnet, daß die Nucleotidsequenz und die Aminosäuresequenz wie folgt sind:
Figure imgb0026
oder
b) einer Nucleotidsequenz zum Codieren der Aminosäuresequenz anderer Protein-A-Materialien, die eine zusätzliche, der Domäne E äquivalente IgG-Bindungsdomäne aufweisen.
2. Rekombinantes DNA-Molekül, mit
a) einer Nucleotidsequenz zum Codieren der Aminosäuresequenz eines Protein-A-Materials, dadurch gekennzeichnet, daß die Nucleotidsequenz und die Aminosäuresequenz folgende sind:
Figure imgb0027
Figure imgb0028
Figure imgb0029
Figure imgb0030
oder
b) einer Nucleotidsequenz zum Codieren der Aminosäuresequenz anderer Protein-A-Materialien, die eine zusätzliche, der Domäne E äquivalente IgG-Bindungsdomäne der obigen Sequenz aufweisen.
3. Mikroorganismus mit einem rekombinanten Plasmid, das eine Nucleotidsequenz nach Anspruch 1 oder 2 enthält.
4. Mikroorganismus mit einem rekombinanten Plasmid, das Fragmente der Nucleotidsequenz zum Codieren der Aminosäuresequenz eines Protein-A-Materials nach Anspruch 2 enthält, wobei diese Fragmente die Domäne E oder die zusätzliche, der Domäne E äquivalente IgG-Bindungsdomäne enthalten.
5. Mikroorganismus mit einem rekombinanten Plasmid, das eine Nucleotidsequenz zum Codieren der Aminosäuresequenz eines Protein-A-Materials nach Anspruch 2 (a) enthält, wobei die letzten 209 Nucleotidsequenzen fehlen.
6. DNA-Transfervektor mit einer eine Aminosäuresequenz codierenden Nucleotidsequenz, wobei die Aminosäuresequenz gemäß Anspruch 2 oder Anspruch 5 ist.
7. Mikroorganismus, umgewandelt durch einen DNA-Transfervektor gemäß Anspruch 6.
8. Das Plasmid von NRRL B-15127 oder NRRL B-15131.
9. E. coli, Depot-Nr. NRRL B-15127 oder NRRL B-15131.
10. Mikroorganismus mit einem rekombinanten Plasmid, das eine Mischung von Nucleotidsequenzen der Domänen D, A, B und C nach Anspruch 2 zur Codierung von Aminosäuresequenzen von Protein-A-Material enthält, dadurch gekennzeichnet, daß die Mischung der Nucleotidsequenzen auch eine Domäne E nach Anspruch 2 oder eine andere zusätzliche, der Domäne E äquivalente IgG-Bindungsdomäne aufweist.
11. Ein im wesentlichen reines biologisches Material, mit einer Nucleotidsequenz zum Codieren der Aminosäuresequenz eines Protein-A-Materials, wobei die Nucleotidsequenz gemäß Anspruch 2 ist.
12. Verfahren zur Herstellung eines Protein-A-Materials, mit einer Ausprägung klonierter DNA nach einem der Ansprüche 1, 2 und 5 zum Codieren des Protein-A-Materials in einem geeigneten mikrobiellen Wirt und Rückgewinnung des Protein-A-Materials.
EP83306500A 1982-10-27 1983-10-26 Protein-A Material und dessen Herstellung Expired - Lifetime EP0107509B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT83306500T ATE71657T1 (de) 1982-10-27 1983-10-26 Protein-a material und dessen herstellung.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US436955 1982-10-27
US06/436,955 US5151350A (en) 1982-10-27 1982-10-27 Cloned genes encoding recombinant protein a

Publications (3)

Publication Number Publication Date
EP0107509A2 EP0107509A2 (de) 1984-05-02
EP0107509A3 EP0107509A3 (en) 1986-03-26
EP0107509B1 true EP0107509B1 (de) 1992-01-15

Family

ID=23734479

Family Applications (1)

Application Number Title Priority Date Filing Date
EP83306500A Expired - Lifetime EP0107509B1 (de) 1982-10-27 1983-10-26 Protein-A Material und dessen Herstellung

Country Status (6)

Country Link
US (1) US5151350A (de)
EP (1) EP0107509B1 (de)
JP (2) JPH0811068B2 (de)
AT (1) ATE71657T1 (de)
CA (1) CA1307483C (de)
DE (1) DE3382495D1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737544A (en) * 1982-08-12 1988-04-12 Biospecific Technologies, Inc. Biospecific polymers
US4691009A (en) * 1984-12-26 1987-09-01 Repligen Corporation Hybrid proteins produced by an ultrahigh prokaryotic expression system
SE459503B (sv) * 1985-05-03 1989-07-10 Excorim Kommanditbolag Hybrid-dna-molekyl innefattande dna-sekvens som kodar foer protein g samt foerfarande foer framstaellning av protein g
DK528285D0 (da) * 1985-11-15 1985-11-15 Novo Industri As Peptider samt praeparater indeholdende disse
EP0234592A1 (de) * 1986-02-28 1987-09-02 Teijin Limited Plasmid, das ein DNA-Fragment enthält, welches für die Fc-Region von menschlichem Immunoglobulin G Protein codiert, und Verwendung desselben zur Herstellung des genannten Proteins
SE459662B (sv) * 1986-03-21 1989-07-24 Pharmacia Ab Hybrid-dna-molekyl som kodar foer ett protein med samma igg specificitet som protein g, plasmid innehaallande densamma samt foerfarande foer framstaellning av proteinet
US4876194A (en) * 1986-07-22 1989-10-24 Hightech Receptor Ab Protein L and subfragments thereof, with immunoglobulin binding activity, a process for preparing thereof, reagent kit, pharmaceutical composition and a peptococcus magnus strain
JPS6348297A (ja) * 1986-08-18 1988-02-29 Sanraku Inc Ｆｃ結合性蛋白質及びその生産菌
EP0289129A3 (de) * 1987-03-26 1990-10-10 Repligen Corporation Herstellung von hochgereinigtem Protein A
US5084559A (en) * 1987-03-27 1992-01-28 Repligen Corporation Protein a domain mutants
DE3887750T2 (de) * 1987-11-20 1994-09-15 Creative Biomolecules Inc Selektive entfernung von immunkomplexen.
US5084398A (en) * 1987-11-20 1992-01-28 Creative Biomolecules Selective removal of immune complexes
US5243040A (en) * 1987-11-20 1993-09-07 Creative Biomolecules DNA encoding a protein which enables selective removal of immune complexes
ES2058538T3 (es) * 1988-07-22 1994-11-01 Imre Corp Compuestos de proteina a purificados y procedimiento para su preparacion.
JP2871709B2 (ja) * 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
JPH02308791A (ja) * 1989-05-24 1990-12-21 Sekisui Chem Co Ltd 免疫グロブリンＦｃ領域に対する結合能力とルシフェラーゼ活性をもつポリペプチド
GB9013872D0 (en) * 1990-06-21 1990-08-15 Inst Tecnologico Y Cientifico Use of protein a and polypeptide components thereof in the treatment of tumours
AU8957091A (en) * 1990-11-26 1992-06-25 Public Health Laboratory Service Board Immunoglobulin-binding proteins and recombinant dna molecules coding therefor
JP2584697B2 (ja) * 1991-08-23 1997-02-26 オリエンタル酵母工業株式会社 ＩｇＧ精製用組換え型プロテインＡ
JP2519136B2 (ja) * 1991-07-25 1996-07-31 オリエンタル酵母工業株式会社 分子量マ−カ−
EP0863210A3 (de) * 1991-07-25 1999-09-22 Oriental Yeast Co., Ltd. Künstliches Immunglobulinkombinierendes Protein
US6001600A (en) * 1996-12-20 1999-12-14 Smithkline Beecham Plc DNA encoding tests polypeptides
GB9526356D0 (en) * 1995-12-22 1996-02-21 Smithkline Beecham Plc Novel compounds
GB9526359D0 (en) * 1995-12-22 1996-02-21 Smithkline Beecham Plc Novel compounds
GB9600955D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Novel compounds
EP1056763A4 (de) * 1998-01-27 2003-03-26 Univ Rockefeller Dns-replikationsproteine von gram-positiven bakterien und ihre anwendung bei der entwicklung von chemischen inhibitoren
US7432365B1 (en) 1998-01-27 2008-10-07 O'donnell Michael E DNA molecules encoding beta clamp proteins of gram positive bacteria
AU6749900A (en) * 1999-07-29 2001-02-19 Rockefeller University, The Dna replication proteins of gram positive bacteria and their use to screen for chemical inhibitors
US20030167524A1 (en) * 2000-12-19 2003-09-04 Rooijen Gijs Van Methods for the production of multimeric protein complexes, and related compositions
NZ526822A (en) * 2000-12-19 2005-03-24 Sembiosys Genetics Inc Methods for the production of multimeric proteins for producing an oil body associated with a recombinant protein complex preferably thioredoxin or an immunoglobin, in transgenic plants and their use in compositons for reducing allergenicity of food
US7098383B2 (en) * 2000-12-19 2006-08-29 Sembiosys Genetics Inc. Methods for the production of multimeric immunoglobulins, and related compositions
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
US20060179514A1 (en) * 2001-07-05 2006-08-10 Sembiosys Genetics, Inc. Methods for the production of multimeric protein complexes, and related compositions
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP2005112827A (ja) * 2003-10-10 2005-04-28 National Institute Of Advanced Industrial & Technology 抗体アフィニティ担体
KR101150050B1 (ko) * 2004-02-27 2012-07-05 지이 헬스케어 바이오-사이언시스 에이비 항체 정제 방법
SE0400501D0 (sv) * 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
CA2570253A1 (en) 2004-07-06 2006-01-12 Kaneka Corporation Process for producing protein a-like protein with use of brevibacillus genus bacaterium
AU2005269527B2 (en) 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
WO2006043896A1 (en) 2004-10-21 2006-04-27 Ge Healthcare Bio-Sciences Ab Chromatography ligand
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
EP1746103A1 (de) 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunktionelle Protein-Anker
US7375188B2 (en) * 2005-07-29 2008-05-20 Mallinckrodt Baker, Inc. Vegetarian protein a preparation and methods thereof
CN106422418B (zh) 2006-09-29 2022-03-01 思拓凡生物工艺研发有限公司 用于抗体分离的包含来自金黄色葡萄球菌a蛋白的结构域c的层析配体
CA2666053C (en) * 2006-12-06 2011-03-29 Repligen Corporation Nucleic acids encoding recombinant protein a
CA2964910C (en) 2007-04-27 2018-01-09 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008146906A1 (ja) 2007-05-30 2008-12-04 Kaneka Corporation ホルミル基含有多孔質担体、それを用いた吸着体、およびそれらの製造方法
SG149759A1 (en) 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
US8338577B2 (en) * 2008-09-15 2012-12-25 Emd Millipore Corporation Methods for quantifying protein leakage from protein based affinity chromatography resins
JP5626526B2 (ja) 2008-09-25 2014-11-19 Jsr株式会社 アフィニティークロマトグラフィー用充填剤
EP2383035A4 (de) 2008-12-03 2017-11-22 Kaneka Corporation Formylgruppenhaltiger poröser träger, adsorbens damit, herstellungsverfahren dafür und verfahren zur herstellung des adsorbens
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
CN102612523B (zh) 2009-04-03 2016-01-20 芝加哥大学 与蛋白a(spa)变体相关的组合物和方法
KR102006097B1 (ko) 2010-03-31 2019-07-31 제이에스알 가부시끼가이샤 친화성 크로마토그래피용 충전제
KR20130093084A (ko) 2010-07-02 2013-08-21 더 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
WO2012124145A1 (ja) 2011-03-15 2012-09-20 オムロン株式会社 演算ユニット、支援装置、支援プログラム、支援プログラムを格納した記憶媒体、および、支援装置における動作方法
SG186552A1 (en) 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
EP2894171A4 (de) 2012-09-10 2016-05-25 Kaneka Corp Adsorptionsmittel
PL2812091T3 (pl) 2012-09-17 2021-07-19 W.R. Grace & Co. - Conn. Podłoża chromatograficzne i urządzenia
TWI675044B (zh) * 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US10189007B2 (en) 2013-10-15 2019-01-29 Kaneka Corporation Method for producing porous cellulose beads and adsorbent employing same
WO2015056680A1 (ja) 2013-10-15 2015-04-23 株式会社カネカ 多孔質セルロースビーズの製造方法
EP3059320A4 (de) 2013-10-15 2017-06-21 Kaneka Corporation Herstellungsverfahren für poröse celluloseperlen und absorptionsmittel damit
EP3094390B1 (de) 2014-01-16 2021-07-07 W.R. Grace & CO. - CONN. Affinitätschromatographiemedien und chromatographievorrichtungen
US20240100450A9 (en) * 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
KR102393642B1 (ko) * 2014-01-17 2022-05-03 리플리겐 코포레이션 크로마토그래피 컬럼 살균
JP6914189B2 (ja) 2014-05-02 2021-08-04 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 官能化担体材料並びに官能化担体材料を作製及び使用する方法
CN107921407B (zh) 2015-06-05 2022-07-05 格雷斯公司 生物处理吸附澄清剂及其制备和使用方法
CN111148753B (zh) 2017-09-25 2024-02-23 Jsr株式会社 免疫球蛋白结合蛋白质和使用其的亲和载体
WO2019059400A1 (ja) 2017-09-25 2019-03-28 Jsr株式会社 イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体
US12187764B2 (en) 2018-06-20 2025-01-07 Jsr Corporation Affinity carrier using mutant VHH antibody
CN112639099B (zh) 2018-08-24 2024-06-28 Jsr株式会社 免疫球蛋白结合蛋白质以及使用其的亲和载体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293652A (en) * 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4322274A (en) * 1980-08-28 1982-03-30 Wilson Gregory B Method of diagnosing cystic fibrosis patients and asymptomatic carrier of the cystic fibrosis gene
SE8204811L (sv) * 1982-08-23 1984-02-24 Sven Lofdahl Dna-fragment innefattande en signalsekvens
SE462046C (sv) * 1982-08-23 1998-04-27 Pharmacia Biotech Ab Hybrid-DNA-vektor innehållande DNA-sekvens från Staphylococcus aureus, förfarande för dess framställning och bakterie innehållande densamma
DE3314812A1 (de) * 1983-04-23 1984-10-25 Battelle-Institut E.V., 6000 Frankfurt Mittel zum antigen/antikoerper-nachweis
US4617266A (en) * 1983-04-28 1986-10-14 Genex Corporation Production of Protein A

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eur. J. Biochem. 78, pp. 471-490 (1977) *

Also Published As

Publication number Publication date
ATE71657T1 (de) 1992-02-15
DE3382495D1 (de) 1992-02-27
JPH08107795A (ja) 1996-04-30
EP0107509A3 (en) 1986-03-26
CA1307483C (en) 1992-09-15
JPH0811068B2 (ja) 1996-02-07
JPS59113890A (ja) 1984-06-30
EP0107509A2 (de) 1984-05-02
US5151350A (en) 1992-09-29

Similar Documents

Publication Publication Date Title
EP0107509B1 (de) Protein-A Material und dessen Herstellung
Hjelm et al. Immunologically active and structurally similar fragments of protein A from Staphylococcus aureus
Sjöbring et al. Streptococcal protein G. Gene structure and protein binding properties.
EP0571538B1 (de) Strukturgen von pneumokokken-protein
AU708061B2 (en) OMP26 antigen from haemophilus influenzae
Nicholson et al. Binding of DNA in vitro by a small, acid-soluble spore protein from Bacillus subtilis and the effect of this binding on DNA topology
JP2981286B2 (ja) 破傷風トキシンフラグメントｃの発現
US7038012B1 (en) Enrichment process for H. pylori neutrophil activating protein (NAP) utilizing metal chelate chromatography
EP0408178A1 (de) Immobilisierte Variante des Proteins G und ihre Verwendung
CA1332366C (en) Leukotoxin gene of pasteurella haemolytica
Chu et al. Cloning and sequence analysis of the muramidase-2 gene from Enterococcus hirae
GB2604692A (en) Method for preparing recombinant subunit vaccine against novel coronavirus
Martinez et al. A single amino acid substitution responsible for altered flagellar morphology
JPS615098A (ja) 殺虫性ポリペプチドをコードする遺伝子
EP0252588A2 (de) Verfahren zur Isolierung und Reinigung von P. falciparum CS-Protein in rekombinantem E. coli sowie seine Verwendung als Impfstoff
RU2260047C2 (ru) Рекомбинантная плазмидная днк, обеспечивающая синтез иммунодоминантного белка borrelia garinii, используемого для диагностики лайм-боррелиоза (варианты)
WO1987005025A1 (en) Cloned streptococcal genes encoding protein g and their use to construct recombinant microorganisms to produce protein g
Ferrazza et al. Biochemical and immunological characterization of an R plasmid-encoded protein with properties resembling those of major cellular outer membrane proteins
CN113480622A (zh) 一种重组肺炎球菌溶血素制备及纯化的方法
McCorquodale et al. Gene D5 product of bacteriophage T5: DNA-binding protein affecting DNA replication and late gene expression
Nakayama Purification of B. subtilis DNA-binding protein related to E. coli HU
Gerlach et al. Isolation and characterization of a mitogen characteristic of group A streptococci (Streptococcus pyogenes)
CN114380897B (zh) 一种结核分枝杆菌包涵体蛋白复性的方法及其专用复性缓冲液
JPH04148685A (ja) 環状プラスミド
CN101991864B (zh) 一种问号钩端螺旋体dna疫苗及其构建方法和应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19860819

17Q First examination report despatched

Effective date: 19880622

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: REPLIGEN CORPORATION

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 71657

Country of ref document: AT

Date of ref document: 19920215

Kind code of ref document: T

ET Fr: translation filed
REF Corresponds to:

Ref document number: 3382495

Country of ref document: DE

Date of ref document: 19920227

ITF It: translation for a ep patent filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 83306500.6

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20021004

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20021008

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20021011

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20021023

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20021029

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20021031

Year of fee payment: 20

Ref country code: DE

Payment date: 20021031

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20021101

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20021219

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20031025

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20031025

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20031025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20031026

Ref country code: LU

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20031026

Ref country code: AT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20031026

BE20 Be: patent expired

Owner name: *REPLIGEN CORP.

Effective date: 20031026

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20031026

EUG Se: european patent has lapsed